NDAINJECTIONINJECTABLE
Approved
Jul 2000
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
4
Data completeness
5/8 — Partial
CEFAZOLIN AND DEXTROSE (cefazolin sodium) by B. Braun is 12. Approved for respiratory tract infections due to streptococcus pneumoniae, staphylococcus aureus, streptococcus pyogenes in adults and 14 more indications. First approved in 2000.
Drug data last refreshed 3h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Cefazolin and Dextrose is a pre-mixed IV antibiotic combination containing cefazolin sodium, a first-generation cephalosporin, in dextrose solution for easy administration. It treats bacterial infections across respiratory, urinary, skin, biliary, bone, joint, and genital sites, as well as septicemia and endocarditis by inhibiting bacterial cell wall synthesis. The pre-filled formulation offers convenience for hospital and surgical settings.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30), indicating potential team contraction or transition to generic defense strategies.
Mechanism of Action
12.1 Mechanism of Action Cefazolin is an antibacterial drug [see ]. 12.2 Pharmacodynamics The pharmacokinetic/pharmacodynamic relationship for cefazolin has not been evaluated in patients. 12.3 Pharmacokinetics Studies have shown that following intravenous administration of cefazolin to normal…
Worked on CEFAZOLIN AND DEXTROSE at B. Braun? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.